Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators (Part 2)
作者:Takafumi Takai、Tatsuki Koike、Minoru Nakamura、Yuichi Kajita、Toshiro Yamashita、Naohiro Taya、Tetsuya Tsukamoto、Tomomichi Watanabe、Koji Murakami、Tomoko Igari、Makoto Kamata
DOI:10.1016/j.bmc.2016.05.040
日期:2016.7
beta (Aβ) without affecting the production of total Aβ or Notch signal, have emerged as a potential therapeutic agent for Alzheimer’s disease (AD). A novel series of 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives was discovered and characterized as GSMs. Optimization of substituents at the 8-position of the core scaffold using ligand-lipophilicity efficiency (LLE) as a drug-likeness guideline
降低致病性淀粉样蛋白β(Aβ)而又不影响总Aβ或Notch信号产生的γ-分泌酶调节剂(GSMs)已成为潜在的治疗阿尔茨海默氏病(AD)的药物。发现了一系列新颖的5,6,7,8-四氢[1,2,4]三唑并[4,3- a ]吡啶衍生物并将其表征为GSM。使用配体亲脂性效率(LLE)作为药物相似性指导方针,对核心支架8位上的取代基进行了优化,从而鉴定了各种类型的高LLE GSM。通过单次给药,苯氧基化合物(R)-17表现出特别高的LLE以及有效的体内Aβ42降低作用。此外,多次口服(R)-使用Tg2576小鼠作为AD模型,在新型对象识别测试(NORT)中,图17显着降低了可溶性和不可溶性大脑Aβ42的水平,并改善了认知缺陷。